by Eosinophilic Esophagitis is a chronic immune/antigen-mediated disease characterized by eosinophil infiltration of the esophageal epithelium and clinical symptoms associated with esophageal dysfunction. Treatments for Eosinophilic Esophagitis include medications like corticosteroids and acid suppressants, which help reduce inflammation and lessen symptoms.
The global Eosinophilic Esophagitis Market is estimated to be valued at US$ 245.92 Mn in 2023 and is expected to exhibit a CAGR of 61% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends
Growing awareness and diagnosis has emerged as a key driver propelling the expansion of the Eosinophilic Esophagitis Market. Factors like the establishment of patient advocacy groups, ongoing research efforts, and the introduction of guideline protocols have collectively helped enhance awareness about the disease among both patients and physicians. This has subsequently resulted in more efficient diagnosis. As diagnosis rates improve, sales opportunities for Eosinophilic Esophagitis drugs are also projected to increase significantly over the forecast period.
SWOT Analysis
Strength: The growing prevalence of eosinophilic esophagitis disease is driving the market growth. Research and development of new treatments is also creating opportunities.
Weakness: Lack of awareness regarding the causes, symptoms and treatment options of eosinophilic esophagitis can hamper the market growth. High cost of treatment can also act as a restraint.
Opportunity: Government support in terms of research funding and initiatives is expected to provide new growth prospects. Rising healthcare expenditure can boost market prospects.
Threats: Stringent regulations for approval of new treatment options can negatively impact the market. Other competitors targeting similar indications can challenge market growth.
Key Takeaways
The global Eosinophilic Esophagitis Market Demand is expected to witness high growth. The global Eosinophilic Esophagitis Market is estimated to be valued at US$ 245.92 Mn in 2023 and is expected to exhibit a CAGR of 61.% over the forecast period 2023 to 2030.
North America holds the largest share of the eosinophilic esophagitis market due to the high prevalence of the disease and the strong presence of key players. Europe is the second-largest market globally with major countries being Germany, U.K., and Italy contributing significantly.
Key players operating in the eosinophilic esophagitis are AutoX, Inc., Baidu, BMW AG, Daimler AG, EasyMile, Ford Motor Company, GM Cruise LLC, Hyundai, Tesla, Inc., and Waymo LLC. The key players are majorly focused on expanding their geographical presence and gaining market share through strategic collaboration and partnerships.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
